Gain Therapeutics GANX Cash Flow Statement (2020-2026)

NASDAQ GANX
$1.71 -0.01 (-0.58%)
At close: Sep 10, 2026 · 4:00 PM EDT
Reported Financials

Gain Therapeutics Quarterly Cash Flow Statement

Periods 26 quarters
Latest Jun 2026

Gain Therapeutics reported cash from operations of -$4.68M and free cash flow of -$4.67M for the quarter ended Jun 2026, up 8.2% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-4.66M-3.22M-3.27M-5.09M-4.56M-4.67M-5.14M-7.69M-4.72M-5.01M-4.01M-8.14M-4.49M-6.28M-4.53M-5.81M-5.28M-2.80M-5.61M-4.68M
Share-based Compensation
0.71M0.17M0.96M1.25M1.92M0.56M2.44M2.60M2.60M0.60M3.53M3.18M3.17M0.36M4.24M4.34M4.13M0.40M4.01M3.86M
Deferred Taxes
-0.04M-0.05M-0.06M-0.12M-0.02M-608.00-0.06M1.65M-0.13M-0.38M0.04M-181.00236.00-0.90M-0.09M-0.21M-0.02M-0.01M
Cash from Operations
-2.19M-4.15M-2.45M-5.05M-3.29M-3.90M-4.22M-5.02M-3.97M-5.66M-3.59M-5.76M-6.08M-3.45M-3.82M-5.10M-4.93M-4.62M-4.73M-4.68M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Depreciation & Amortization
0.00M0.01M0.01M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.03M0.02M0.03M
Change in Working Capital
Change in Receivables
-0.33M-0.02M
Change in Account Payables
1.54M
Change in Accured Expenses
1.16M-0.59M1.74M-0.51M0.30M-0.82M1.06M-0.68M-0.05M-1.03M0.70M1.48M-1.85M-0.06M1.11M0.15M-0.95M-0.79M0.53M-0.49M
Change in Taxes
Other Working Capital Changes
-0.60M0.59M1.22M-0.35M-0.48M-0.27M0.55M-0.39M-0.18M-0.03M0.30M0.40M0.02M-0.36M0.84M0.41M-0.87M-0.52M0.28M0.22M
Investing Activities
Capital Expenditures
0.32M-0.28M0.01M0.04M-0.20M0.27M0.01M0.00M650.0019.000.00M0.02M608.00338.00-927.00-851.00-541.00-533.00913.00-0.01M
Change in Acquisitions & Divestments
2.07M4.07M3.05M1.93M3.14M3.02M2.02M-0.04M
Cash from Investing Activities
-0.03M-0.01M-0.01M-14.89M-0.01M0.13M2.11M3.05M1.93M3.14M3.02M2.00M-1.00-0.04M
Financing Activities
Other financing activities
0.10M0.01M1.00-1.000.04M1.30M0.00M
Debt Issuance and Repayment
Long-Term Debt Issuances
Short-Term Debt issuances
0.04M-0.00M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.03M0.03M0.03M
Change in Capital Stock
Net Shares Issued and Repurchased
0.54M1.01M0.56M0.72M1.10M1.40M1.10M1.20M0.80M
Net Equity Issued and Repurchased
0.77M2.22M0.16M0.75M2.37M5.64M8.30M13.64M0.40M1.50M
Misc.
Cash from Financing Activities
-0.01M-0.04M0.00M-0.02M-0.02M0.75M2.20M0.13M9.56M-0.15M10.04M0.81M2.31M2.40M2.47M7.03M16.55M0.40M1.37M
Exchange Rate Effect
0.03M0.06M-0.05M-0.09M-0.11M0.23M0.04M0.11M-0.14M0.48M-0.44M0.01M0.38M-0.48M0.11M0.26M0.01M0.10M0.02M-0.14M
Change in Cash
-2.19M-4.10M-2.54M-20.03M-3.43M-3.57M-1.32M0.33M-2.05M7.53M-1.16M6.30M-4.88M-1.67M-1.31M-2.37M2.11M12.03M-4.30M-3.46M
Free Cash Flow
-2.51M-3.87M-2.46M-5.10M-3.08M-4.18M-4.23M-5.03M-3.97M-5.66M-3.59M-5.77M-6.08M-3.45M-3.82M-5.10M-4.93M-4.62M-4.73M-4.67M
Net Cash Flow
-2.22M-4.17M-2.49M-19.94M-3.32M-3.79M-1.36M0.22M-1.90M7.04M-0.71M6.28M-5.27M-1.19M-1.42M-2.63M2.11M11.93M-4.32M-3.31M